Case Report
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2018; 6(7): 150-155
Published online Jul 16, 2018. doi: 10.12998/wjcc.v6.i7.150
Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature
Ning-Ning Yang, Fei Xiong, Qing He, Yong-Song Guan
Ning-Ning Yang, Fei Xiong, Qing He, Yong-Song Guan, Department of Oncology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Yang NN, Xiong F and He Q performed the operation and collected clinical data; Guan YS helped to design, write and revise the paper.
Informed consent statement: Witten informed consent was obtained from the patient and his family before all procedures described in the report as well as for the use of the patient’s clinical information and images for publication.
Conflict-of-interest statement: All the authors declare that there is no conflict of interest related to this report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yong-Song Guan, MD, PhD, Professor, Department of Oncology, West China Hospital of Sichuan University, 37 Guoxuexiang Street, Chengdu 610041, Sichuan Province, China. yongsongguan@yahoo.com
Telephone: +86-28-85423278 Fax: +86-28-85423278
Received: February 22, 2018
Peer-review started: February 22, 2018
First decision: March 12, 2018
Revised: March 15, 2018
Accepted: April 22, 2018
Article in press: April 22, 2018
Published online: July 16, 2018
Processing time: 144 Days and 12 Hours
Abstract

Surgery is the first choice of treatment for patients with non-small-cell lung cancer (NSCLC), but few patients can be treated surgically because of either advanced disease or poor pulmonary function. Other therapies include radiotherapy and chemotherapy, as well as complementary and alternative therapies, usually with disappointing results. Bronchial artery infusion (BAI) is a manageable and effective method for treating advanced NSCLC. Outcome is good by BAI due to its repeatability and low toxicity. Icotinib hydrochloride is a newly developed and highly specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and has been safely and efficiently used to treat advanced NSCLC. We herein report a 73-year-old patient with chronic cough, who was diagnosed with advanced NSCLC with the EGFR mutation of L858R substitution in exon 21, and treated with the combination of oral icotinib and BAI chemotherapy as the first-line therapy, which resulted in a satisfactory clinical outcome. Complete remission of advanced NSCLC can be achieved using the combination of oral icotinib and BAI chemotherapy.

Keywords: Tyrosine kinase inhibitor; Bronchial artery infusion; Icotinib hydrochloride; Epidermal growth factor receptor; Advanced non-small-cell lung cancer

Core tip: Few patients can undergo surgery for treatment of non-small-cell lung cancer because of advanced disease or poor pulmonary function. Combination of bronchial artery infusion of anti-cancer agents and oral targeted drug is safe, tolerable, and effective for patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer (NSCLC). Complete remission of advanced NSCLC can be achieved by this combination therapy.